Abeona Therapeutics (ABEO) Q2 2024 earnings summary

Executive summary

• Significant progress made in addressing FDA's Complete Response Letter (CRL) for pz-cel, with nearly all CMC issues resolved and only two validation items outstanding; BLA resubmission planned for H2 2024 after Type A meeting with FDA.

• Commercial launch preparations for pz-cel are advancing, including cGMP facility readiness, site onboarding, payer engagement, and strong stakeholder feedback.

• Entered a non-exclusive agreement with Beacon Therapeutics to evaluate AAV204 capsid for ophthalmology gene therapies.

• Preclinical pipeline includes AAV-based gene therapies for genetic eye diseases, with pre-IND meetings completed.

Financial highlights

• Net income for Q2 2024 was $7.4 million, driven by a $24.9 million gain from warrant liability remeasurement, compared to a net loss of $16.7 million in Q2 2023.

• Cash, cash equivalents, short-term investments, and restricted cash totaled $123 million as of June 30, 2024, up from $62.7 million at March 31, 2024.

• Research and development expenses were $9.2 million and general and administrative expenses were $8.6 million for Q2 2024, both higher year-over-year due to launch preparations.

• Net cash used in operating activities was $12.7 million for Q2 2024.

• Sufficient financial resources to fund operations into 2026, excluding potential pz-cel revenue or PRV proceeds.

Outlook and guidance

• BLA resubmission for pz-cel expected in the second half of 2024, with FDA review anticipated to set a PDUFA date six months post-resubmission.

• Commercial launch of pz-cel targeted approximately three months after potential approval.

• Ongoing payer discussions indicate favorable coverage prospects for pz-cel.

• Cash runway extends well beyond anticipated regulatory milestones and commercial launch.

• Continued investment in commercialization and R&D expected to result in ongoing operating losses for the foreseeable future.